Crossref journal-article
Springer Science and Business Media LLC
Journal of Cancer Research and Clinical Oncology (297)
Bibliography

Kikuchi, Y., Kita, T., Miyauchi, M., Hirata, J., Sasa, H., Nagata, I., & Fukushima, M. (1992). Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. Journal of Cancer Research and Clinical Oncology, 118(6), 453–457.

Authors 7
  1. Y. Kikuchi (first)
  2. T. Kita (additional)
  3. M. Miyauchi (additional)
  4. J. Hirata (additional)
  5. H. Sasa (additional)
  6. I. Nagata (additional)
  7. M. Fukushima (additional)
References 16 Referenced 22
  1. Bregman MD, Meyskens FL Jr (1983) In vitro modulation of human and murine melanoma growth by prostanoid analogues. Prostaglandins 26:449–456 (10.1016/0090-6980(83)90179-X) / Prostaglandins by MD Bregman (1983)
  2. Bregman MD, Funk, C, Fukushima M (1986) Inhibition of human melanoma growth by prostaglandin A, D, and J analogues. Cancer Res 46:2740–2744 / Cancer Res by MD Bregman (1986)
  3. Eisenbarth GS, Wellman DK, Leibovitz HE (1974) PGA1 inhibition of chondrosarcoma growth. Biochem Biophys Res Commun 60:1302–1308 (10.1016/0006-291X(74)90339-8) / Biochem Biophys Res Commun by GS Eisenbarth (1974)
  4. Fukushima M Kato T, Ueda R, Ota K, Narumiya S, Hayaishi O (1982a) Prostaglandin D2, a potential antineoplastic agent. Biochem Biophys Res Commun 105:956–964 (10.1016/0006-291X(82)91063-4) / Biochem Biophys Res Commun by M Fukushima (1982)
  5. Fukushima M, Kato T, Ota K, Arai Y, Narumiya S, Hayaishi O (1982b) 9-Deoxy-delta9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle contracting activities. Biochem Biophys Res Commun 109:626–633 (10.1016/0006-291X(82)91986-6) / Biochem Biophys Res Commun by M Fukushima (1982)
  6. Honn KV, Dunn JR, Morgan LR, Bienkowski M, Marnett LJ (1979) Inhibition of DNA synthesis in Harding-Passey melanoma cells by prostaglandins A1 and A2: comparison with chemotherapeutic agents. Biochem Biophys Res Commun 87:795–801 (10.1016/0006-291X(79)92028-X) / Biochem Biophys Res Commun by KV Honn (1979)
  7. Kato T, Fukushima M, Kurozumi S, Noyori R (1986) Antitumor activity of Δ7-prostaglandin A1, and Δ12-prostaglandin J2 in vitro and in vivo. Cancer Res 46:3538–3542 / Cancer Res by T Kato (1986)
  8. Kawamura M, Koshihara Y (1983) Prostaglandin D2 strongly inhibits growth of murine mastocytoma cells. Prostaglandins Leukotrienes med 12:85–93 (10.1016/0262-1746(83)90071-9) / Prostaglandins Leukotrienes med by M Kawamura (1983)
  9. Kikuchi Y, Miyauchi M, Oomori K, Kita T, Kizawa I, Kato K (1986) Inhibition of human ovarian cancer cell growth in vitro and in nude mice by prostaglandin D2. Cancer Res 46:3364–3366 / Cancer Res by Y Kikuchi (1986)
  10. Kikuchi Y, Miyauchi M, Iwano I, Kita T, Oomori K, Kizawa I (1988) Adjuvant effects of prostaglandin D2 to cisplatin on human ovarian cancer cell growth in nude mice. Eur J Cancer Clin Oncol 24:1829–1833 (10.1016/0277-5379(88)90093-4) / Eur J Cancer Clin Oncol by Y Kikuchi (1988)
  11. Lane M (1979) Clinical problem of resistance to cancer chemotherapeutic agents. Fed Proc 38:103–107 / Fed Proc by M Lane (1979)
  12. Narumiya S, Fukushima M (1985) Delta12-prostaglandin J2, an ultimate metabolite of prostaglandin D2 exerting cell growth inhibition. Biochem Biophys Res Commun 127:739–745 (10.1016/S0006-291X(85)80005-X) / Biochem Biophys Res Commun by S Narumiya (1985)
  13. Sakai T, Yamaguchi N, Shirosko Y, Sekiguchi M, Fujii G, Nishino H (1984) Prostaglandin D2 inhibits the proliferation of human malignant tumor cells. Prostaglandins 27:17–27 (10.1016/0090-6980(84)90217-X) / Prostaglandins by T Sakai (1984)
  14. Santoro MG, Philpott GW, Jaffe BM (1976) Inhibition of tumor growth in vivo and in vitro by prostaglandin E. Nature 263:777–779 (10.1038/263777a0) / Nature by MG Santoro (1976)
  15. Sasaki H, Takada K, Terashima Y, Ekimoto H, Takahashi K, Tsuruo T, Fukushima M (1991) Human ovarian cancer cell lines resistant to cisplatin, doxorubicine andl-phenylalanine mustard are sensitive to Δ12-prostaglandin A1 and Δ12-prostaglandin J2. Gynecol Oncol 41:36–40 (10.1016/0090-8258(91)90251-Y) / Gynecol Oncol by H Sasaki (1991)
  16. Simmet T, Jaffe BM (1983) Inhibition of B-16 melanoma growth in vitro by prostaglandin D2. Prostaglandins 25:47–54 (10.1016/0090-6980(83)90134-X) / Prostaglandins by T Simmet (1983)
Dates
Type When
Created 20 years, 3 months ago (May 8, 2005, 10:26 a.m.)
Deposited 6 years, 3 months ago (May 7, 2019, 2:38 p.m.)
Indexed 11 months, 3 weeks ago (Sept. 7, 2024, 10:37 p.m.)
Issued 33 years, 3 months ago (June 1, 1992)
Published 33 years, 3 months ago (June 1, 1992)
Published Print 33 years, 3 months ago (June 1, 1992)
Funders 0

None

@article{Kikuchi_1992, title={Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells}, volume={118}, ISSN={1432-1335}, url={http://dx.doi.org/10.1007/bf01629429}, DOI={10.1007/bf01629429}, number={6}, journal={Journal of Cancer Research and Clinical Oncology}, publisher={Springer Science and Business Media LLC}, author={Kikuchi, Y. and Kita, T. and Miyauchi, M. and Hirata, J. and Sasa, H. and Nagata, I. and Fukushima, M.}, year={1992}, month=jun, pages={453–457} }